Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
eurofins.com

See what CB Insights has to offer

Investments

1

Partners & Customers

10

About Eurofins Scientific

Eurofins Scientific (Paris: ERF) (EUFI.PA) provides testing and support services to the pharmaceutical, food, environmental, agriscience, and consumer products industries. The company was founded in 1987 and is based in Luxemburg.

Eurofins Scientific Headquarter Location

Val Fleuri 23

Luxembourg, 1526,

Luxembourg

+352 261 85 320

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Eurofins Scientific Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Eurofins Scientific Rank

Latest Eurofins Scientific News

Eurofins Strengthens Its Comprehensive Food Testing Offering in Japan Through the Acquisition of QSAI Analysis and Research Center Co.,Ltd.

Aug 12, 2022

August 12, 2022 01:15 AM Eastern Daylight Time Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in food testing and a global scientific leader in bioanalytical testing, announces the signing of an agreement to acquire a majority stake in QSAI Analysis and Research Center Co.,Ltd. (“QARC”). QARC was founded in 2013 as a spin-off from QSAI’s R&D center and has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving an extensive customer base in the food, wholesale and retail industries as well as institutions and governments. QARC is recognised as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC employs 80 people in its laboratories in Fukuoka and Nagoya and is accredited against ISO/IEC 17025 and The Ministry of Health, Labour and Welfare (MHLW). The acquisition of QARC will complement the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign object and sensory testing services. The acquisition will further strengthen Eurofins’ presence in Japan and the Eurofins network’s offering to customers importing and exporting food products. About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world. In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19. Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP). Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity. Contacts Investor Relations

Eurofins Scientific Investments

1 Investments

Eurofins Scientific has made 1 investments. Their latest investment was in Galys Laboratoire as part of their Secondary Market on July 7, 2019.

CBI Logo

Eurofins Scientific Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/16/2019

Secondary Market

Galys Laboratoire

Yes

1

Date

7/16/2019

Round

Secondary Market

Company

Galys Laboratoire

Amount

New?

Yes

Co-Investors

Sources

1

Eurofins Scientific Acquisitions

90 Acquisitions

Eurofins Scientific acquired 90 companies. Their latest acquisition was WESSLING Hungary on July 29, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/29/2022

$99M

Acquired Unit

1

6/27/2022

$99M

Acquired

1

6/2/2022

$99M

Corporate Majority

2

5/31/2022

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/27/2022

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/29/2022

6/27/2022

6/2/2022

5/31/2022

5/27/2022

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Acquired

Corporate Majority

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Eurofins Scientific Partners & Customers

10 Partners and customers

Eurofins Scientific has 10 strategic partners and customers. Eurofins Scientific recently partnered with Ginkgo Bioworks on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/28/2022

Partner

United States

Clinical Enterprise, Inc. and Ginkgo Bioworks to Continue Support of Federal COVID-19 Testing Program Through 2022

`` Through this ongoing partnership with Clinical Enterprise , Inc. , we 've been able to equip community leaders with tools they can use to generate the information they need to protect the most vulnerable members of their communities , '' said Matt McKnight , General Manager for Biosecurity at Ginkgo Bioworks .

1

5/9/2022

Client

PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology (“PAMM”) to Eurofins Clinical Diagnostics Netherlands

Eurofins Scientific , a global scientific leader in bioanalytical testing , announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie , a medical microbiology and pathology laboratory diagnostics company in The Netherlands .

1

5/9/2022

Client

PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology (“PAMM”) to Eurofins Clinical Diagnostics Netherlands

LUXEMBOURG -- -- Eurofins Scientific , a global scientific leader in bioanalytical testing , announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie , a medical microbiology and pathology laboratory diagnostics company in The Netherlands .

2

1/13/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

1/13/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

7/28/2022

5/9/2022

5/9/2022

1/13/2022

1/13/2022

Type

Partner

Client

Client

Vendor

Vendor

Business Partner

Country

United States

United States

United States

News Snippet

Clinical Enterprise, Inc. and Ginkgo Bioworks to Continue Support of Federal COVID-19 Testing Program Through 2022

`` Through this ongoing partnership with Clinical Enterprise , Inc. , we 've been able to equip community leaders with tools they can use to generate the information they need to protect the most vulnerable members of their communities , '' said Matt McKnight , General Manager for Biosecurity at Ginkgo Bioworks .

PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology (“PAMM”) to Eurofins Clinical Diagnostics Netherlands

Eurofins Scientific , a global scientific leader in bioanalytical testing , announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie , a medical microbiology and pathology laboratory diagnostics company in The Netherlands .

PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology (“PAMM”) to Eurofins Clinical Diagnostics Netherlands

LUXEMBOURG -- -- Eurofins Scientific , a global scientific leader in bioanalytical testing , announces that it has successfully signed an agreement with Stichting PAMM Laboratoria voor Pathologie en Medische Microbiologie , a medical microbiology and pathology laboratory diagnostics company in The Netherlands .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Eurofins Scientific Team

9 Team Members

Eurofins Scientific has 9 team members, including current Chief Operating Officer, Christian Wurst.

Name

Work History

Title

Status

Christian Wurst

Chief Operating Officer

Current

J. Michael Drozd

President

Former

Daniel Bednar

Chief Financial Officer, Executive Vice President

Former

Carey Lewis

Senior Vice President

Former

David L. Morgan II

LabCorp, United States Marine Corps, and US LABS

Senior Vice President

Former

Name

Christian Wurst

J. Michael Drozd

Daniel Bednar

Carey Lewis

David L. Morgan II

Work History

LabCorp, United States Marine Corps, and US LABS

Title

Chief Operating Officer

President

Chief Financial Officer, Executive Vice President

Senior Vice President

Senior Vice President

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.